Global Mucopolysaccharidosis (MPS) Treatment Industry Set to Reach US$ 3.37 Billion by 2029, Reports Future Market Insights

The Global Mucopolysaccharidosis (MPS) Treatment Industry is poised for significant growth, with a projected valuation of US$ 3.37 billion by 2029, as stated in a comprehensive market study presented by Future Market Insights (FMI). In 2022, the market is estimated to be worth approximately US$2.38 billion, showcasing a strong Compound Annual Growth Rate (CAGR) of 5.9% between 2022 and 2029. This remarkable growth is attributed to the increasing prevalence of mucopolysaccharidosis (MPS) worldwide.

Mucopolysaccharidosis, a rare and complex group of disorders, currently lacks a universally accepted treatment pattern. While various geographies have implemented standard treatment options, the field of MPS remains ever-evolving, with a significant shortage of medical and scientific data pertaining to the condition. Mucopolysaccharidosis treatment and diagnosis require intricate management, including long-term care, rehabilitation support, and continuous treatment planning.

FMI’s market study titled “Global Mucopolysaccharidosis (MPS) Treatment Industry Trend: Global Industry Analysis 2014-2021 and Opportunity Assessment 2022-2029” sheds light on the critical factors shaping the current market landscape. It underscores the need for innovative approaches and therapies in the realm of MPS treatment.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-5880

Research Activities Uplift Stem Cell Therapy Application in Global Mucopolysaccharidosis (MPS) Treatment Industry

In the present scenario, the drugs that are considered for mucopolysaccharidosis treatment, such as aldurazyme, naglazyme, vimizim, elaprase, mepsevii and hunterase, are the only regulated and recommended drugs present in the market. These drugs fall under enzyme replacement therapies, however, with present research initiatives for stem cell therapies, the latter is considered a prominent mucopolysaccharidosis treatment. Clinical research shows that stem cell transplantation covers a large area that is not covered with the more frequently recommended practice of enzyme replacement therapies, which changes the current market structure for mucopolysaccharidosis treatment, prioritising the latter.

Stem cell therapy is a therapeutic option for mucopolysaccharidosis patients suffering from a severe phenotype, as research shows the method can preserve neurocognition or can even help break the progressive neurodegeneration. The method is provided with strict selection criteria, which is followed by maintained regulations. Research shows that stem cell therapy as a treatment option is gaining popularity among healthcare professionals for mucopolysaccharidosis treatment, which can be attributed to the relation of its better reach towards a normal health condition for the patient.

Delving into the study’s assumptions. Ask the Expert
https://www.futuremarketinsights.com/ask-question/rep-gb-5880

Enzyme Replacement Therapy Remains Lucrative for Market Investors

As per further assessments of the Global Mucopolysaccharidosis (MPS) Treatment Industry , it has been difficult to collect epidemiological data pertaining to rare diseases, especially mucopolysaccharidosis treatment, which is likely to impede the actual estimation of the economic burden associated with the condition. The cost estimation for each mucopolysaccharidosis treatment type is affecting and, in turn, creating a more vulnerable situation for the businesses and disrupting research & development activities for each company.

Enzyme replacement therapy is the most attractive segment for investors, however, the unavailability of reimbursement plans and precise treatment plans is encouraging most patient in developing regions to opt for symptomatic treatments instead of enzyme replacement therapy, which is still considered to be the standard mucopolysaccharidosis treatment.

Key Players Focus on Clinical Research of Treatment Models

The report segments the mucopolysaccharidosis treatment market into seven regions to elaborate on the regional trends pertaining to the treatment plan. Major players are focusing on increasing their market share in the Asia Pacific market through strategic collaborations with regional research institutes. There is a lack of awareness about rare diseases among the general public as well as in medical healthcare facilities in several emerging economies. According to a survey and industry report, it takes patients in the US an average of 7.6 years and patients in the UK an average of 5.6 years to actually receive a proper diagnosis. Moreover, it involves a team of healthcare professionals to actually get the right mucopolysaccharidosis treatment and diagnosis pattern for reported cases.

Lead with Confidence: Access Your Customized Report.
https://www.futuremarketinsights.com/customization-available/rep-gb-5880

Manufacturers are in the process of introducing a considerable number of mucopolysaccharidosis treatment options, which are currently under clinical trials. An estimated 160 and above clinical trials are being performed for mucopolysaccharidosis treatment. Thus, ensuring that the manufacturers take this mucopolysaccharidosis treatment market to be lucrative and potential rich in terms of revenue. Medical research institutes play an important role in this particular market. They are expected to be the bridge between treatment plans and economical solutions for manufacturers, thus leaving an explicable and lucrative model for mucopolysaccharidosis treatment.

The Global Mucopolysaccharidosis (MPS) Treatment Industry includes companies such as BioMarin Takeda Pharmaceutical Company Limited, Sanofi S.A., and Ultragenyx Pharmaceutical Inc. BioMarin accounts for a significant value share in the present Global Mucopolysaccharidosis (MPS) Treatment Industry. The currently existing promising drug types are expected to face competition from emerging candidates. In addition, the mucopolysaccharidosis treatment products of other companies, such as Sangamo Therapeutics, Inc., REGENXBIO Inc., Sarepta Therapeutics, Abeona Therapeutics, Inc., and others, are also in the pipeline.

Global Mucopolysaccharidosis (MPS) Treatment Industry by Category Treatment

• Enzyme Replacement Therapies
• Stem Cell Therapies
  • Bone Marrow Transplantation
  • Umbilical Cord Blood Transplantation

Type of MPS

• MPS I
• MPS II
• MPS IV A
• MPS VI
• MPS VII

End User

• Hospital
• Specialty Clinics
• Medical Research Centers
• Home-infusion

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube